Optimal treatment for small hepatocellular carcinoma (HCC) ≤ 3 cm remains controversial. Ablation and chemoembolization are considered for nonoperative candidates. This study compares survival among patients with solitary HCC ≤ 3 cm treated with radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). Patients diagnosed with HCC ≤ 3 cm between 2005 and 2014 were included. Kaplan-Meier survival functions with log-rank tests were used to estimate recurrence-free survival and overall survival (OS) survival. Among 161 patients with solitary HCC ≤ 3 cm, 145 patients with mean age of 65.2 years (±9.2) and 95 per cent prevalence of cirrhosis had operative treatment or TACE, and/or RFA. From this cohort, 27 (19%) patients had TACE, 27 (19%) patients had RFA, and 15 (10%) patients had TACE/RFA. The patients treated with definitive TACE, RFA, or TACE/RFA had a similar 1-year recurrence-free survival (23% 27% 36%, respectively, = 0.445) and similar 5-year OS (21% 24% 33%, respectively, = 0.287). Thirty-five (24%) patients were bridged to transplantation with TACE and/or RFA. The 5-year OS was significantly improved in patients bridged to transplantation ( < 0.001). Survival does not differ between patients with solitary HCC ≤ 3 cm treated with TACE or RFA. Patients who were bridged to transplantation had significantly greater OS compared with patients who were not transplanted.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study.
JHEP Rep
January 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
Background & Aims: Current prognostic models for patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) are not extensively validated and widely accepted. We aimed to develop and validate a continuous model incorporating tumor burden and biology for individual survival prediction and risk stratification.
Methods: Overall, 4,377 treatment-naive candidates for whom TACE was recommended, from 39 centers in five countries, were enrolled and divided into training, internal validation, and two external validation datasets.
Multi-clustering study on the association between human leukocyte antigen and hepatitis B virus-related hepatocellular carcinoma and cirrhosis in Viet Nam.
World J Gastroenterol
December 2024
Medical Technology Department, Hanoi Medical University, Hanoi 116177, Viet Nam.
Background: Human leukocyte antigen (HLA) class II molecules are cell surface receptor proteins found on antigen-presenting cells. Polymorphisms and mutations in the gene can affect the immune system and the progression of hepatitis B.
Aim: To study the relation between rs2856718 of , rs3077, and rs9277535 of , hepatitis B virus (HBV)-related cirrhosis, and hepatocellular carcinoma (HCC).
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort.
Hepatol Commun
November 2024
Department of Gastroenterology, Hepatology, Infectiology and Endocrinology, Hannover Medical School, Hannover, Germany.
Article Synopsis
- Immunotherapy combinations are the standard treatment for advanced hepatocellular carcinoma (HCC), with growing evidence supporting lenvatinib as a strong first-line option.
- A retrospective study analyzed 412 patients treated with either atezolizumab/bevacizumab (AZ/BV) or lenvatinib (LEN) across 18 European hospitals, revealing that those on AZ/BV experienced longer progression-free survival.
- Despite comparable survival rates between the two treatments overall, AZ/BV posed a higher risk of liver issues in patients with pre-existing liver function impairment, highlighting the need for careful patient monitoring.
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases.
J Hepatocell Carcinoma
October 2024
Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
Purpose: To evaluate safety, preliminary efficacy, pharmacokinetics, and pharmacodynamics, of fostroxacitabine bralpamide (fostrox, MIV-818), a novel oral troxacitabine nucleotide prodrug designed to direct exposure to the liver, while minimizing systemic toxicity.
Patients And Methods: Fostrox monotherapy was administered in an open-label, single-arm, first-in-human, phase 1a/1b study, in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, or solid tumor liver metastases. The first part (1a) consisted of intra/inter-patient escalating doses (3 mg to 70 mg) QD for up to 5 days, and the second part (1b), doses of 40 mg QD for 5 days, in 21-day cycles.
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study.
Liver Cancer
October 2024
Toronto General Hospital, UHN, Toronto, ON, Canada.
Article Synopsis
- The RATIONALE-301 study compared the cancer treatments tislelizumab and sorafenib in adults with unresectable hepatocellular carcinoma, finding tislelizumab met the goal of noninferiority in overall survival.
- The research utilized various health-related quality of life (HRQOL) assessments and revealed that patients on tislelizumab reported better HRQOL outcomes, particularly in aspects of fatigue and physical functioning, compared to those on sorafenib.
- Overall, tislelizumab not only showed better quality of life results but also had a favorable safety profile, marking it as a promising first-line treatment option for patients with hepatocellular carcinoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!